KRAS and pancreatic neoplasm: Briefly, robust levels of macropinocytosis have been demonstrated in PDAC cell lines that harbor oncogenic KRAS mutations, observed in tumors of KPC mice (LSL-KRASG12D; TP53R172H/+; Pdx1-Cre; a transgenic spontaneous pancreatic cancer mouse model), and meaningfully, detected in human PDAC tumor samples regardless of some intratumoral variability.